Holding your nose and investing in value
So what do value investing and a medical treatment known as ‘FMT’ have in common? You might want to finish eating before you read any further…
Here on The Value Perspective, we never shy away from a strong analogy as we seek to convey the benefits of a value-oriented investment strategy.
Still, while what follows is unarguably strong, we appreciate it may also be pushing the boundaries of good taste and so, should you be in the habit of reading our articles while eating lunch at your desk, say, you may wish to finish that sandwich first.
Because what we are about to discuss is the process of Faecal Microbiota Transplantation, which we learned about from Ed Yong’s eye-opening exploration of the world of microbes, I Contain Multitudes, and involves the treatment of certain gastrointestinal diseases through the patient – there really is no delicate way of putting this – ingesting freeze-dried pellets of a healthy person’s faeces.
No, that would not be our first choice of a cure either and yet, if you were suffering from clostridium difficile infection, for example, ‘FMT’ really does seem to be what you should be asking your doctor to prescribe.
In 2013, writes Yong, a particularly robust set of trials showed this to be highly effective where antibiotics tend to struggle and it has been regulated by the US’s notably fastidious Food & Drug Administration ever since.
And the value parallel?
Well, like FMT, a value investment strategy involves going against every instinct you have to do the thing you least want to do – voluntarily taking on board something other people have quite literally discarded and go out of their way to avoid.
Those brave enough to do so are in a position to benefit from a highly effective process that history shows can lead to a very good result. We will leave it there.
Past performance is not a guide to future performance and may not be repeated.
Fund Manager, Equity Value
I joined Schroders as a graduate in 2005 and have spent most of my time in the business as part of the UK equities team. Between 2006 and 2010 I was a research analyst responsible for producing investment research on companies in the UK construction, business services and telecoms sectors. In mid 2010 I joined Kevin Murphy and Nick Kirrage on the UK value team.
The views and opinions displayed are those of Nick Kirrage, Andrew Lyddon, Kevin Murphy, Andrew Williams, Andrew Evans, Simon Adler, Juan Torres Rodriguez, Liam Nunn, Vera German and Roberta Barr, members of the Schroder Global Value Equity Team (the Value Perspective Team), and other independent commentators where stated.
They do not necessarily represent views expressed or reflected in other Schroders' communications, strategies or funds. The Team has expressed its own views and opinions on this website and these may change.
This article is intended to be for information purposes only and it is not intended as promotional material in any respect. Reliance should not be placed on the views and information on the website when taking individual investment and/or strategic decisions. Nothing in this article should be construed as advice. The sectors/securities shown above are for illustrative purposes only and are not to be considered a recommendation to buy/sell.
Past performance is not a guide to future performance and may not be repeated. The value of investments and the income from them may go down as well as up and investors may not get back the amounts originally invested.